Literature DB >> 3161094

A facilitatory role for serotonin in the sexual behavior of the female rat.

S D Mendelson, B B Gorzalka.   

Abstract

The peripheral administration of the serotonin type 2 receptor (5-HT2) antagonist pirenperone inhibited sexual receptivity in ovariectomized female rats primed either chronically with estradiol benzoate (EB), or acutely with EB plus varying doses of progesterone. An inhibition occurred at 50, 100 and 150 but not 25 micrograms/kg pirenperone. Increasing the dose of progesterone did not attenuate the inhibitory effect of pirenperone. Two other 5-HT2 antagonists, ketanserin (2.5 mg/kg) and spiperone (250 micrograms/kg), also inhibited receptivity in females primed with EB and progesterone. The inhibitory effect of pirenperone on receptivity was attenuated by the 5-HT agonist quipazine (3 mg/kg), though quipazine alone had no effect on receptivity. Whereas the 5-HT antagonist methysergide (3 mg/kg) failed to have an effect on receptivity in EB-primed females, methysergide co-administered with quipazine facilitated receptivity. Pirenperone also inhibited proceptivity in females primed with EB and progesterone. Although quipazine did not attenuate the pirenperone-induced inhibition of proceptivity, quipazine alone increased proceptivity. Moreover, quipazine facilitated proceptivity in EB-primed rats whether progesterone was present or absent. The results suggest that 5-HT may serve both a facilitatory and inhibitory role in female sexual behavior, perhaps reflecting 5-HT2 and 5-HT1 receptor activity, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161094     DOI: 10.1016/0091-3057(85)90313-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  5-HT1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats.

Authors:  F Jenck; C L Broekkamp; A M Van Delft
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality.

Authors:  Yves Aubert; Morgan L Gustison; Lindsey A Gardner; Michael A Bohl; Jason R Lange; Kelly A Allers; Bernd Sommer; Nicole A Datson; David H Abbott
Journal:  J Sex Med       Date:  2012-02-03       Impact factor: 3.802

3.  Comparison of female Fischer and Sprague-Dawley rats in the response to ketanserin.

Authors:  Chandra Suma Johnson Miryala; Cindy Hiegel; Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2013-11-04       Impact factor: 3.533

4.  Regulation of pseudosexual behavior in the parthenogenetic whiptail lizard, Cnemidophorus uniparens.

Authors:  Brian George Dias; David Crews
Journal:  Endocrinology       Date:  2008-05-15       Impact factor: 4.736

Review 5.  The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

Authors:  Sheryl A Kingsberg; Anita H Clayton; James G Pfaus
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 6.  Pharmacology of serotonin and female sexual behavior.

Authors:  Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2013-11-15       Impact factor: 3.533

7.  Evidence for the involvement of central 5-HT1A receptors in the mediation of lordosis behavior in the female rat.

Authors:  S Ahlenius; K Larsson; A Fernandez-Guasti
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation.

Authors:  Mary K Holder; Jessica A Mong
Journal:  Curr Sex Health Rep       Date:  2017-10-16

9.  Experimental and Numerical Study on the Failure Characteristics of Brittle Solids with a Circular Hole and Internal Cracks.

Authors:  Chengjun Le; Xuhua Ren; Haijun Wang; Shuyang Yu
Journal:  Materials (Basel)       Date:  2022-02-14       Impact factor: 3.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.